Here is a very attractive and brutally undervalued canadian company called Medicenna (MDNA.TO) which is listed since March thats why its also undicovered . This Cancer Play has a Phase 2 trial in recurrent Glioblastoma ongoing a $650 Million Market , they expect to complete enrollment by year end and to report results in early Q1 2018 . If the results are positive then they can file for accelerated approval in 2H 2018 and this makes this company with a terrible low valuation of only C$ 36 Million a super attractive opportunity which has 10 bagger potential easily on positive phase 2 results in Q1 2018 and FDA approval .Please do your own DD and realize the mega potential .GL Medicenna Therapeutics (MDNA.TO) Market Cap C$36 Million Cash : C$ 20 Million << enough untill Q1 2019 Price : $1.50 Shares Out: 24.3 Million ( 15.5 Million shares held by Insider alone ) Medicenna Therapeutics (TSXV: MDNA) CEO: Our Drug Has Potential for Phase 2 Approval https://smallcappower.com/videos/companies-to-watch/medicenna-therapeutics-tsxv-mdna/ New Presentation http://s21.q4cdn.com/710416940/file.../Medicenna-Corporate-Presentation-Q3-2017.pdf Fact Sheet http://s21.q4cdn.com/710416940/files/doc_downloads/fact_sheet/Medicenna-FS-Q1-2017-v2.pdf Insider Ownership : Aries Biologics, Inc. 5 500 000 Rosemina Merchant 5 050 000 Fahar Merchant 5 050 000 Elizabeth Williams 5 300 Chandrakant J. Panchal, PhD 1 000 Trevor P. Wong-Chor 714
Nice move today , this unknown low float rocket will run to $10 and higher with positive results in Q1 and FDA approval .GL http://ih.advfn.com/p.php?pid=webchart&symbol=TSX:mdna&period=0&size=19&volume=1
Small Phase 2b trial has huge chance to be successful because it was already successfull in prior studies so this stock like to be above $10 after phase 2 results in early Q1 . And that Management holding 15+ million shares of the 24.3 million shares outstanding makes me also optimistic .GL MDNA55 is enrolling patients in a Phase 2b clinical trial for rGB at leading brain cancer centres in the US. MDNA55 has completed 3 clinical trials in 72 patients, including 66 adults with rGB, demonstrated compelling efficacy and obtained Fast-Track and Orphan Drug status from USFDA. Unlike most other cancer therapies, Medicenna's IL4-ECs have the potential to purge both the tumor and the immunosuppressive tumor microenvironment, Medicenna Phase 2b trial using Brainlab technology http://www.biotuesdays.com/briefs/2017/6/8/medicenna-phase-2b-trial-using-brainlab-technology The current Phase 2b clinical trial plans to enroll 43 adult patients with rGB at leading brain cancer centers in the U.S.